Ipamorelin 5mg

Ipamorelin is a synthetic pentapeptide cataloged in public chemical databases and described in peer-reviewed literature as a selective growth hormone secretagogue research compound [1] [2] [3]. Research procurement requires review of compound identity, COA, analytical testing, lot traceability, and supplier documentation. Published literature does not establish effects for the supplied material.

• Ipamorelin is treated here as a research peptide, not as a clinical, wellness, fitness, or consumer product.
• Researchers evaluating where to buy Ipamorelin for research should review product documentation before commercial language.
• Compound identity review should compare name, formula, molecular weight, sequence information, and lot-specific records.
• Published literature can inform receptor and pathway context, but it does not create product-use claims.
• COA documentation should be batch-specific and should align with the product label and supplier records.
• HPLC and LC-MS documentation can support peptide purity review and identity verification when interpreted correctly.

Fast Answer: What Should Researchers Check Before They Buy Ipamorelin for Research?

Research buyers should check RUO labeling, batch-specific COA availability, peptide identity data, purity testing, LC-MS or comparable identity verification, lot matching, supplier documentation, and storage records before they buy Ipamorelin for research. Products discussed in this article are intended for laboratory research use only and are not intended for human or animal consumption. Scientific literature should be read as model-specific context, not product positioning.

For research teams, the commercial question becomes: does the listing provide enough documentation to evaluate the compound as a laboratory material? That means a clear research-use-only label, a compound name that matches the COA, and a lot number that connects the physical material to its analytical file.

What Documentation Should Come First?

Start with the product label, certificate of analysis, and batch-specific testing records. A COA should identify the compound, lot, test date, assay method, and purity or identity result in a way that can be matched to the research material.

Analytical guidance from ICH and FDA describes validation concepts for procedures used to evaluate identity, purity, assay, and related measurements [19] [20]. Those official frameworks are not a substitute for supplier-specific files, but they explain why method clarity matters.

Why Does RUO Labeling Matter Before Technical Review?

RUO labeling sets the boundaries for how the page, product records, and supporting literature should be interpreted. FDA’s RUO guidance for IVD products illustrates the core distinction between laboratory research labeling and diagnostic positioning, while 21 CFR 809.10 includes the familiar research-only labeling concept in the IVD setting [27] [28].

Ipamorelin is supplied for laboratory research. Evaluation includes documentation review and analytical verification; academic pathway findings do not establish effects for a Pure Lab Peptides product.

What Is Ipamorelin in Research Literature?

Ipamorelin appears in chemical and bioactivity databases as a peptide compound with the molecular formula C38H49N9O5 and an approximate molecular weight of 711.9 g/mol [1] [2]. Peer-reviewed literature describes Ipamorelin as a pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 [3].

That identity information is useful for product-page review because it gives laboratory buyers a baseline for checking supplier documentation. If the product label, COA, database identity, and analytical records do not align, the listing needs closer review.

Ipamorelin Is a Synthetic Peptide in Research Context

Ipamorelin is a synthetic peptide classified in the growth hormone secretagogue research lane [3]. In the literature, its relevance comes from receptor-pathway research, not from product claims.

Published studies describe specific research materials and experimental conditions. A supplied RUO material requires its own characterization and supplier documentation.

Why Is Pentapeptide Identity Important for Documentation?

A pentapeptide contains five amino-acid residues. For Ipamorelin, sequence-level identity helps researchers compare product documentation against published compound descriptions and database records [1] [3].

Sequence, molecular weight, and molecular formula are technical reference points for label review, COA comparison, and identity verification.

How Do Published Sources Frame GH Secretagogue Research?

The growth hormone secretagogue receptor, also known as GHSR or the ghrelin receptor, was identified as a receptor involved in endocrine signaling research [4]. Ghrelin was later described as an endogenous acylated peptide ligand for that receptor pathway [5].

Ipamorelin literature fits into that broader GHSR research context. The safe interpretation is pathway context: receptor literature helps explain why the compound appears in endocrine pathway research, not what a product does.

Ipamorelin Research Peptide Identity and Classification

Ipamorelin research peptide evaluation starts with identity. The key question is whether the material being reviewed matches the documented compound.

Public records can support this review. PubChem provides chemical identity data, ChEMBL provides bioactivity-oriented compound information, and peer-reviewed literature provides sequence and receptor-class context [1] [2] [3].

Peptide Sequence, Molecular Weight, and Formula Review

A practical documentation review compares three layers: formula, molecular weight, and sequence. Ipamorelin’s database formula and mass should be checked against the COA and the supplier’s listing [1] [2].

Sequence confirmation is more demanding than reading a purity percentage. Peptide analysis often requires complementary methods, because chromatographic purity and molecular identity answer related but different questions [21] [22].

What Should Researchers Verify About Receptor Binding?

GHSR is a G-protein-coupled receptor, and official gene and protein databases describe it as a ghrelin receptor involved in receptor signaling [9] [10]. Interpret receptor findings in relation to the study model and conditions.

Published ligand-receptor findings provide scientific context; procurement review also requires documentation for the supplied batch.

Scientific Background for GH Secretagogue and GHRH Research

GH secretagogue and GHRH research overlaps around endocrine pathway models, but the receptor systems are different. GHSR literature centers on ghrelin-receptor signaling, while GHRH research centers on the growth hormone-releasing hormone receptor.

Ghrelin Receptor Context for Ipamorelin Research

Ghrelin receptor research includes receptor discovery, endogenous ligand identification, and intracellular signaling models [4] [5] [6]. Reviews describe GHSR signaling as a complex receptor system with ligand-regulated and constitutive activity considerations [6] [7].

This literature provides background on Ipamorelin’s receptor research context; it does not establish effects for a supplied RUO material.

Pituitary Cell Models in Published Research

Pituitary cell literature appears often in this research area because GHRH and GHSR pathways are studied in endocrine signaling models. GHRHR is described by NCBI Gene as a receptor for growth hormone-releasing hormone, and UniProt describes the receptor as coupled to G proteins that activate adenylyl cyclase [11] [12].

These receptor findings do not establish effects or suitability for a supplied research material.

How Do GHRH Signal Models Differ From GHSR Models?

GHRH signal models center on GHRHR and cAMP-related signaling in pituitary cell systems [13] [14]. GHSR signal models center on ghrelin receptor activation, receptor conformation, and intracellular signaling pathways [6] [8].

CJC-1295 and Ipamorelin require separate identity and documentation review because their receptor contexts differ.

Receptor and Signaling Pathways Context for Ipamorelin

Ipamorelin research includes GHSR, ghrelin receptor context, selectivity, and model-specific GH pathway findings.

Pathway relevance means the compound appears in a research model; it does not define a use case for a research material.

What Does Selectivity Mean in Receptor Research?

Selectivity means a compound is described in literature as having a more focused receptor or pathway profile than comparator compounds under study conditions. The original Ipamorelin literature characterized it as selective in GH secretagogue research and discussed pituitary hormone markers such as prolactin in the context of selectivity evaluation [3].

Signal Transduction Concepts for Laboratory Models

Signal transduction is the chain of molecular events that follows ligand-receptor interaction. Reviews of GHSR describe intracellular signaling, receptor regulation, and ligand-dependent activity as areas of ongoing research [6] [7].

CJC-1295 and Ipamorelin: Different Receptor Contexts

CJC-1295 and Ipamorelin relate to GHRH and GH secretagogue research, respectively, but they are distinct compounds.

Research on one compound does not establish findings for another compound or for a combined material. Each requires its own identity and batch documentation.

How Does CJC-1295 Peptide Context Differ From Ipamorelin?

CJC-1295 is discussed in the literature as a GHRH analog, while Ipamorelin is discussed as a GH secretagogue research peptide associated with GHSR literature [3] [15]. The receptor context differs: GHRH analog research points toward GHRHR, while Ipamorelin research points toward GHSR [9] [11].

Same category does not mean same identity.

Evidence Limits for Combined Materials

Published CJC-1295 literature can support background on GHRH analog research, but it does not automatically support claims about CJC-1295 and Ipamorelin materials together [15] [18].

Identify each compound separately and compare its documentation with the material evaluated in the original study.

PubChem maintains separate entries for CJC-1295 and CJC1295 without DAC, which shows why exact compound naming matters in documentation review [16] [17].

Catalog specifications should remain secondary to identity, COA, and lot documentation.

Published Literature Interpretation for Research Buyers

Research buyers should read literature by evidence type. A database entry, receptor study, preclinical model, and analytical chemistry paper all answer different questions.

Why Does Study Design Matter for Evidence Weighting?

Study design matters because a receptor model, database entry, and analytical method paper do not carry the same meaning. A receptor study can explain pathway context, while a COA and analytical file help evaluate a specific batch.

Research buyers should not flatten all evidence into one “proof” category. A safer evidence ladder is: database identity, peer-reviewed pathway context, model-specific findings, analytical documentation, and supplier-specific batch records.

What Are the Limits of Research Models?

Research models are limited by their design, conditions, and scope. Some published literature outside the scope of RUO product use has examined this compound class in human study settings. That literature should not be interpreted as a use claim for research-use-only materials.

A product listing identifies a supplied research material; clinical findings cannot be assumed to apply to that material.

Why Is Literature Context Not Product-Claim Evidence?

Literature context is not product-claim evidence because published studies evaluate specific compounds, models, and methods under defined research conditions. A supplier listing is a separate artifact that needs its own COA and lot-level documentation.

Scientific context explains the studied pathways; supplier documentation supports procurement review.

COA Documentation for Ipamorelin Peptide Review

A certificate of analysis is one of the most important records on a research product page. It should help connect the listed compound to a batch-specific analytical result.

A strong COA review does not stop at a purity number. It asks whether the compound name, lot number, testing method, date, and lab source align with the product documentation.

What Should a Certificate of Analysis Clarify?

A COA should clarify compound identity, lot number, testing date, assay method, and reported analytical findings. ICH Q2(R2) explains that analytical procedures may be used for identity, purity, impurity, assay, and related measurements, which is why the method field matters [19].

For peptide materials, COA interpretation should be conservative. The COA should support documentation review, not replace independent technical judgment.

Lot Number, Test Date, and Batch Matching Review

Lot traceability connects a specific research material to a specific analytical record. If the product label and COA do not share a matching lot number, the documentation chain is incomplete.

Test date also matters. It helps the laboratory buyer determine when the analytical record was generated and whether it reasonably supports the listed material.

How Do Researchers Compare COA Consistency Across Materials?

Researchers can compare COA consistency by reviewing the same fields across supplier files: compound name, lot number, test method, purity result, identity method, lab source, and date.

Reference-standard literature also shows why well-characterized standards and coordinated analytical approaches matter for peptide quality evaluation [24].

Purity, HPLC, and LC-MS Testing for Research Materials

Purity and identity are related, but not identical. HPLC can help review chromatographic purity, while LC-MS can help evaluate molecular identity and related impurity characterization [21] [22] [23].

The strongest documentation set often combines method disclosure, chromatographic data, identity-oriented mass data, and batch matching. A single percentage without method context is less informative.

How Does HPLC Support Peptide Purity Review?

HPLC separates mixture components and produces chromatographic peaks that can be interpreted in relation to retention time, peak area, and separation quality [21] [25]. For peptide work, reversed-phase and other HPLC modes have long been used in analysis and purification contexts [21].

For product-page review, HPLC supports purity assessment. It does not, by itself, prove full identity.

How Does LC-MS Support Identity Verification?

LC-MS combines chromatographic separation with mass spectrometry. Mass spectrometry measures ion signals by mass-to-charge ratio, which can support molecular identity review when paired with appropriate method data and reference expectations [22] [26].

For synthetic peptides, LC-MS workflows can also help characterize impurities and confirm molecular features relevant to batch documentation [22] [23]. That makes LC-MS especially useful when the product page claims identity support.

Analytical Verification Workflow for Ipamorelin Research

Analytical verification connects the listed research material with its supporting records. Review the following documentation before procurement.

1. Verify the compound name, lot number, and product label match across supplier files.
2. Review the batch-specific certificate of analysis.
3. Check whether the purity testing method is clearly listed.
4. Confirm whether identity testing is supported by LC-MS, mass spectrometry, or another suitable analytical method.
5. Review chromatogram or mass data when available.
6. Check the COA date and lab source.
7. Document storage and handling conditions in a laboratory record.

This workflow is for laboratory documentation review, not non-research use.

Mass Spectrometry Data for Technical Review

Mass spectrometry data can support technical review by comparing observed mass-related signals to expected compound identity. NCBI’s mass spectrometry overview explains that MS outputs mass-to-charge information, while LC-MS peptide literature describes its role in synthetic peptide characterization [22] [26].

For Ipamorelin documentation, the key is whether the supplier file shows enough identity-oriented data to support the product listing.

What Does Third-Party Testing Add to Supplier Review?

Third-party testing can add separation between the supplier’s commercial listing and the analytical record. It does not remove the need to review the method, lot match, and reporting details.

A third-party file is most useful when it identifies the compound, names the method, lists the lot, and provides interpretable data. Without those elements, the claim of outside testing is less useful.

Traceability, Labeling, and Supplier Documentation

Traceability is the record chain that connects a product listing to a batch and a batch to analytical documentation. For research buyers, this chain is often the most practical way to compare suppliers.

The documentation matrix should include product label, COA, test method, lot number, date, storage note, and supplier contact record. Each field helps confirm that the material being reviewed is the same material described in the supporting files.

Storage Documentation and Labeling Consistency

Storage documentation should be recorded as a laboratory handling requirement, not as a claim about product performance. The product label and supplier documentation should use consistent compound naming and lot identification.

Labeling consistency also supports internal laboratory records. If the label, COA, and listing use different names or unclear synonyms, the discrepancy should be resolved before procurement.

Research Procurement Checklist Before You Buy Ipamorelin for Research

Before selecting any research-use-only peptide, procurement teams should complete a documentation checklist.

• Verify that the compound is labeled for research use only.
• Review the batch-specific certificate of analysis.
• Confirm that purity data are supported by analytical testing.
• Check that the lot number on the COA matches the product documentation.
• Compare compound name, molecular weight, formula, and sequence information across records.
• Assess whether the product page avoids non-RUO claims.
• Document storage and handling requirements in a laboratory record.

What Should Research Buyers Compare Across Supplier Files?

Research buyers should compare supplier files for consistency, specificity, and traceability. The best files tell one coherent story: same compound, same lot, clear method, current record, and RUO label.

For peptide materials, analytical completeness matters. HPLC and LC-MS documentation are complementary because one supports purity review while the other supports identity-oriented review [21] [22].

Next-Step Documentation Review for Laboratory Research Use

The next step is to review the product-page documentation, COA details, and RUO labeling before evaluating Ipamorelin for laboratory research. If documents are missing, unclear, or not batch-specific, the listing deserves additional review.

Research buyers should be able to understand what is listed, what is documented, and where the research boundary begins.

Common Misunderstandings in Ipamorelin Research Procurement

First, published literature does not equal product-use guidance. Second, pathway relevance does not equal a product claim. Third, a purity percentage does not prove complete compound identity. Fourth, catalog specifications are listing details, not research conclusions. Fifth, RUO labeling does not support non-research positioning.

Research-Use-Only Notice and Next Steps

Pure Lab Peptides supplies compounds for laboratory research use only. Products are not intended for human or animal consumption, diagnostic use, therapeutic use, clinical use, veterinary use, or as food, drugs, cosmetics, dietary supplements, or household products. Researchers are responsible for ensuring lawful, appropriate handling and use in accordance with applicable regulations and institutional guidelines.

Review the product-page documentation, COA details, and RUO labeling before evaluating this compound for laboratory research.

FAQs

What should researchers consider before they buy Ipamorelin for research?

Researchers should consider documentation quality before they buy Ipamorelin for research. A research-use-only review should prioritize compound identity, COA consistency, lot traceability, analytical testing, and supplier documentation.

What role does the pituitary gland play in Ipamorelin research context?

The pituitary gland appears in Ipamorelin research context because GH secretagogue literature often examines endocrine pathway models.

How do growth hormone secretagogues fit into this research category?

Growth hormone secretagogues are compounds studied in relation to GH secretagogue receptor pathways and endocrine signaling models. Ipamorelin is examined within this research category.

How does Ipamorelin differ from GHRP-2 and GHRP-6 in research literature?

Ipamorelin, GHRP-2, and GHRP-6 are distinct research compounds and are not interchangeable. Compare each by identity, receptor literature, analytical documentation, and supplier records; findings do not establish non-research uses.

What Can In Vitro Research Show?

In vitro research can show how a compound is examined under controlled laboratory model conditions. For Ipamorelin, those findings should be interpreted as research context only. They do not replace COA review, analytical testing, peptide identity verification, or batch-specific documentation for a research-use-only material.

Researchers Cited in This Guide

The researchers listed below are cited for relevant published work. Their inclusion does not imply that they wrote, reviewed, or endorsed this guide or Pure Lab Peptides products.

Masayasu Kojima

Author profile: KAKEN Researcher Profile

Masayasu Kojima’s published ghrelin research provides context for ghrelin, the growth hormone secretagogue receptor, and endocrine signaling models relevant to Ipamorelin’s broader research background.

Selected publications:

• Ghrelin is a growth-hormone-releasing acylated peptide from stomach — Nature, 1999. DOI: 10.1038/45230. PMID: [10604470]
• Ghrelin: structure and function — Physiological Reviews, 2005. DOI: 10.1152/physrev.00012.2004. PMID: [15788704]

Michael T. Boyne II

Author profile: Google Scholar

Michael T. Boyne II’s analytical chemistry publications address LC-MS, mass spectrometry, peptide identity, and quality control. This work provides background on orthogonal methods, verification and validation, and system suitability in the characterization of peptide and protein materials.

Selected publications:

• A publication examining LC-HRMS for peptide quality control — The AAPS Journal, 2015. DOI: 10.1208/s12248-015-9730-z. PMID: [25716148]
• A publication examining LC-MS peptide mass mapping system suitability — mAbs, 2015. DOI: 10.1080/19420862.2015.1074364. PMID: [26218711]

REFERENCES

1. NIH PubChem. Ipamorelin compound record. PubChem Compound Database. Updated record accessed 2026.
2. European Bioinformatics Institute. IPAMORELIN compound record. ChEMBL. CHEMBL58547.
3. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin research pharmacology source. European Journal of Endocrinology. 1998;139(5):552–561. DOI: 10.1530/eje.0.1390552. PMID: 9849822.
4. Howard AD, Feighner SD, Cully DF, et al. GHSR receptor discovery source. Science. 1996;273(5277):974–977. DOI: 10.1126/science.273.5277.974. PMID: 8688086.
5. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin ligand discovery source. Nature. 1999;402(6762):656–660. DOI: 10.1038/45230. PMID: 10604470.
6. Yin Y, Li Y, Zhang W. Growth hormone secretagogue receptor signaling review. International Journal of Molecular Sciences. 2014;15(3):4837–4855. DOI: 10.3390/ijms15034837. PMID: 24651458.
7. Cornejo MP, Mustafá ER, Cassano DA, Banères JL, Raingo J, Perello M. GHSR signaling review. FEBS Journal. 2021;288(24):7213–7229. DOI: 10.1111/febs.15718. PMID: 33460513.
8. Liu H, Sun D, Myasnikov A, et al. Human ghrelin receptor structural signaling study. Nature Communications. 2021;12:6410. DOI: 10.1038/s41467-021-26735-5. PMID: 34737341.
9. National Center for Biotechnology Information. GHSR gene record. NCBI Gene. Gene ID: 2693.
10. UniProt Consortium. GHSR protein record. UniProtKB. Accession Q92847.
11. National Center for Biotechnology Information. GHRHR gene record. NCBI Gene. Gene ID: 2692.
12. UniProt Consortium. GHRHR protein record. UniProtKB. Accession Q02643.
13. Mayo KE, Miller T, DeAlmeida V, Godfrey P, Zheng J, Cunha SR. GHRH receptor and pituitary somatotroph review. Recent Progress in Hormone Research. 2000;55:237–266. PMID: 11036940.
14. Horváth JE, Groot K, Schally AV. GHRH and cAMP pituitary cell source. Proceedings of the National Academy of Sciences of the United States of America. 1995;92(6):1856–1860. DOI: 10.1073/pnas.92.6.1856. PMID: 7892191.
15. Jetté L, Léger R, Thibaudeau K, et al. CJC-1295 GHRH analog research source. Endocrinology. 2005;146(7):3052–3058. DOI: 10.1210/en.2004-1286. PMID: 15817669.
16. NIH PubChem. CJC-1295 compound record. PubChem Compound Database. CID 91971820.
17. NIH PubChem. CJC1295 without DAC compound record. PubChem Compound Database. CID 91976842.
18. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. CJC-1295 GHRH analog study. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799–805. PMID: 16352683.
19. International Council for Harmonisation. Q2(R2) Validation of Analytical Procedures. ICH Harmonised Guideline. 2023.
20. U.S. Food and Drug Administration. Q2(R2) Validation of Analytical Procedures. FDA Guidance Document. 2024.
21. Mant CT, Chen Y, Yan Z, et al. HPLC analysis and purification of peptides. Methods in Molecular Biology. 2007. PMID: 18604941.
22. Lian Z, et al. Synthetic peptide characterization by LC-MS. Journal of the American Society for Mass Spectrometry. 2021. DOI: 10.1021/jasms.0c00479. PMID: 34110145.
23. Zeng K, Geerlof-Vidavisky I, Gucinski A, Jiang X, Boyne MT II. LC-HRMS for peptide quality control. AAPS Journal. 2015;17(3):643–651. DOI: 10.1208/s12248-015-9730-z. PMID: 25716148.
24. McCarthy D, Han Y, Carrick K, Atouf F. Reference standards for synthetic peptide quality. Pharmaceutical Research. 2023. DOI: 10.1007/s11095-023-03493-1. PMID: 36949371.
25. Premnath SM, et al. Chromatography overview. StatPearls, NCBI Bookshelf. Updated 2024.
26. Garg E, et al. Mass spectrometer overview. StatPearls, NCBI Bookshelf. Updated 2024.
27. U.S. Food and Drug Administration. Distribution of IVD Products Labeled for Research Use Only or Investigational Use Only. FDA Guidance for Industry and FDA Staff. 2013.
28. Electronic Code of Federal Regulations. 21 CFR 809.10 labeling for in vitro diagnostic products. eCFR. Current as accessed 2026.

Research Disclaimer

This material is supplied strictly for in vitro laboratory research and is not for human or veterinary use. Published studies describe specific experimental materials, models, and methods; they do not establish the safety, efficacy, or suitability of this catalog product for non-research use. Review the original publications and the lot-specific analytical documentation independently.